Elon Musk kills Tesla Model S and Model X because of ‘autonomy’

Tesla announced on its Q4 2025 earnings call that it will discontinue the Model S and Model X by the end of Q2 (the article gives both 2026 and 2025 dates) and will repurpose Fremont’s production line—currently capable of 100,000 annual S/X units but running well below capacity—for Optimus humanoid robot production, citing "autonomy" as the rationale. “Other models” deliveries (which include Cybertruck and Semi) totaled 50,850 in FY2025 with quarterly figures of Q4 2024: 23,640; Q1 2025: 12,881; Q2 2025: 10,394; Q3 2025: 15,933; Q4 2025: 11,642; the author estimates true S/X deliveries nearer 30,000 in 2025. The move follows a modest June refresh and price increases (Model S to $84,990; Model X to $89,990), and comes amid competitive pressure from Lucid and Rivian, implying reduced strategic priority for low-volume luxury EVs and operational restructuring risk for investors.

Analysis

Market structure: Discontinuing Model S/X frees up ~100k Fremont capacity (currently underutilized; S/X ~30k units in 2025) and signals persistent weak demand for $80k+ Teslas. Winners: luxury EV peers (LCID), robotics/hardware suppliers tied to Optimus (motors, sensors, advanced semis), and legacy OEMs picking up premium EV share. Losers: Tesla high-margin ASP mix, used S/X residuals, and Fremont blue-collar employment economics that could raise one-time costs.

Risk assessment: Near-term equity volatility and IV spikes are probable over days-weeks as investors price in conversion capex and potential impairments; expect 1–2 quarters with restructuring charges and possible Fremont downtime. Tail risks: Optimus R&D failure (>$3–5bn downside over 2 years), FTC/SEC scrutiny over autonomy claims, and union/labor litigation in CA. Catalysts to watch: next 2 quarterly filings for impairment/reserve line items, FSD regulatory rulings in 3–9 months, and any public Optimus demos within 6–12 months.

Trade implications: Direct: bias toward modest short/hedge on TSLA equity and long selective luxury EV exposure (LCID) capturing displaced S/X buyers; options: buy 3–6 month TSLA put spreads to cap cost. Cross-sector: increase exposure to AI/robotics-dedicated semis (e.g., NVDA) by +1–2% portfolio weight for 6–18 months to capture Optimus and FSD compute demand. Timing: act within 1–4 weeks for equity rebalancing, use 3–6 month options to trade volatility spikes.

Contrarian angles: Consensus underprices the redeployment optionality—Fremont could be repurposed to raise Model Y/3 or Cybertruck output, adding ~30–50k incremental volume and $1.2–2.5bn revenue/year if executed in 12–24 months. Also, market may over-penalize TSLA before FSD subscription monetization or a pragmatic pause on Optimus; these would trigger a sharp mean-reversion. Risk: if Optimus succeeds, suppliers and NVDA-like names could see outsized multiple expansion.

Key Decisions for Investors

• Trim TSLA longs by ~50% within 5 trading days and initiate a 6-month downside hedge: buy TSLA Jun-2026 10% OTM puts and sell a further 25% OTM put (put-spread) sized to protect remaining exposure, capping hedge cost while insuring against a >20% decline.
• Establish a 1–2% net-long position in LCID within 2–4 weeks (target 20–40% upside over 6–12 months); place stop-loss at -30% and size to be dollar-neutral vs reduced TSLA exposure as a relative-value play for premium EV share capture.
• Overweight semiconductor/AI hardware exposure (e.g., NVDA) by +1–2% of portfolio within 3 months to capture potential Optimus/FSD compute demand; consider 12-month call overlays if willing to pay volatility for leverage (target 15–30% return).
• Implement a pair trade: short TSLA and long LCID equal-dollar (1–2% portfolio each) to isolate idiosyncratic Tesla execution risk; unwind if TSLA underperforms LCID by 15% or after 9 months.
• Within 30 days, review Tesla’s next 10-Q/earnings release for: (a) explicit Fremont capex reallocation amounts, (b) impairment/one-time charges >$500m, and (c) stated timeline to convert capacity; only increase TSLA exposure if communicated capex is < $1bn and Optims/robotics milestones are independently verified.